Immunotherapy and PARP Inhibitor for Advanced or Metastatic Breast, Ovarian or Pancreatic Cancer with a BRCA Mutation
Clinicaltrials.gov identifier:
NCT04673448
Treatment study for people with advanced breast, ovarian or pancreatic cancer and an inherited or tumor BRCA mutation
Combining the Immunotherapy Dostarlimab and PARP Inhibitor Niraparib for Advanced or Metastatic Breast, Ovarian or Pancreatic Cancer with an Inherited or Tumor BRCA Mutation
About the Study
NOTE: This study is no longer recruiting people.
This study is looking at the effectiveness of combining a called and an called dostarlimab for treating people with an inherited mutation (found with genetic testing) or a tumor mutation (found through tumor testing) who have breast, pancreatic, ovarian, or primary peritoneal cancer that is or advanced and cannot be removed by surgery (unresectable).
NOTE: This study is no longer recruiting people.
NOTE: This study is no longer recruiting people.